Logo Image
|Articles|July 4, 2020

Specialty Pharmacy Times

  • June 2020
  • Volume 3
  • Issue 2

Hereditary Angioedema: Management Updates for the Specialty Pharmacist

This continuing education activity is supported by an educational grant from Takeda.

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA.

FACULTY

Melanie B. Radi, PharmD, CSP

Manager, Clinical Programs Specialty Clinical Services

AllianceRx Walgreens Prime

Pittsburgh, Pennsylvania

At the completion of this activity, the participant will be able to:

  • Characterize the diagnosis and background of hereditary angioedema (HAE) and the significance of early intervention
  • Examine the clinical data of FDA-approved agents and emerging therapies for acute treatment and prophylaxis of HAE
  • Explore the need for individualized treatment and the role of the specialty pharmacist in patient education for effective HAE management

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: May 15, 2020

EXPIRATION DATE: May 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.

Articles in this issue

about 6 years ago

Timely Antiviral Administration for Influenza Is Critical to Reduce Its Clinical and Economic Burden

about 6 years ago

Relapsed or Refractory Follicular and Mantle Cell Lymphomas: Pharmacist-Driven Strategies to Optimize Patient Management

about 6 years ago

CIDP Care: A Patient and Clinical Experts Weigh In

over 6 years ago

Emerging Strategies in the Treatment and Management of Idiopathic Pulmonary Fibrosis

over 6 years ago

JAK Inhibitors Are Important Tools for Patients With Myelofibrosis

over 6 years ago

Examining the Use of Immunoglobulin for Primary Immunodeficiency Disorders

over 6 years ago

Hereditary Angioedema: Only Appropriate Pharmacotherapy Reduces Overall Costs

over 6 years ago

Specialty Pharmacists Have Broad Responsibilities in Chronic Lymphocytic Leukemia

over 6 years ago

New Agents for Myelodysplastic Syndromes May Reduce Transfusion Requirements

over 6 years ago

The Multidisciplinary Team Improves Cystic Fibrosis Outcomes

Related to this article

View more
Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Read more